MX2021002885A - Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet). - Google Patents

Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet).

Info

Publication number
MX2021002885A
MX2021002885A MX2021002885A MX2021002885A MX2021002885A MX 2021002885 A MX2021002885 A MX 2021002885A MX 2021002885 A MX2021002885 A MX 2021002885A MX 2021002885 A MX2021002885 A MX 2021002885A MX 2021002885 A MX2021002885 A MX 2021002885A
Authority
MX
Mexico
Prior art keywords
bromodomain
bet
proteins
manufacturing
solid form
Prior art date
Application number
MX2021002885A
Other languages
English (en)
Spanish (es)
Inventor
Henrik C Hansen
Feng Wen
Mark T Edgar
Jiahui Chen
Xianghui Wen
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of MX2021002885A publication Critical patent/MX2021002885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
MX2021002885A 2018-09-13 2019-09-13 Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet). MX2021002885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730849P 2018-09-13 2018-09-13
PCT/IB2019/001011 WO2020053657A1 (en) 2018-09-13 2019-09-13 Method of manufacturing a solid form of a bet bromodomain inhibitor

Publications (1)

Publication Number Publication Date
MX2021002885A true MX2021002885A (es) 2021-07-15

Family

ID=69777480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002885A MX2021002885A (es) 2018-09-13 2019-09-13 Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet).

Country Status (14)

Country Link
US (2) US12145932B2 (cg-RX-API-DMAC7.html)
EP (2) EP3849980B1 (cg-RX-API-DMAC7.html)
JP (2) JP7731794B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210080373A (cg-RX-API-DMAC7.html)
CN (1) CN112955449B (cg-RX-API-DMAC7.html)
AU (1) AU2019338059B2 (cg-RX-API-DMAC7.html)
CA (1) CA3111527A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190598A1 (cg-RX-API-DMAC7.html)
ES (1) ES3034982T3 (cg-RX-API-DMAC7.html)
IL (1) IL281258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002885A (cg-RX-API-DMAC7.html)
SG (1) SG11202102497SA (cg-RX-API-DMAC7.html)
TW (1) TWI882964B (cg-RX-API-DMAC7.html)
WO (1) WO2020053657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
TW202327594A (zh) 2021-09-23 2023-07-16 大陸商恒翼生物醫藥(上海)股份有限公司 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
KR102619331B1 (ko) * 2021-11-30 2023-12-29 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
KR102307566B1 (ko) * 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
WO2017075377A1 (en) * 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) * 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
TWI816880B (zh) 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
TWI841598B (zh) 2018-09-13 2024-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 用於治療雌激素受體陽性乳癌之組合療法
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Also Published As

Publication number Publication date
EP4588919A1 (en) 2025-07-23
US20250034142A1 (en) 2025-01-30
EP3849980B1 (en) 2025-04-23
EP3849980A1 (en) 2021-07-21
TW202024078A (zh) 2020-07-01
IL281258B1 (en) 2025-11-01
AU2019338059B2 (en) 2025-03-20
CN112955449A (zh) 2021-06-11
JP2022500433A (ja) 2022-01-04
KR20210080373A (ko) 2021-06-30
WO2020053657A1 (en) 2020-03-19
US20220048905A1 (en) 2022-02-17
IL281258B2 (en) 2026-03-01
CA3111527A1 (en) 2020-03-19
TWI882964B (zh) 2025-05-11
SG11202102497SA (en) 2021-04-29
US12145932B2 (en) 2024-11-19
AU2019338059A1 (en) 2021-04-01
ES3034982T3 (en) 2025-08-27
JP7731794B2 (ja) 2025-09-01
JP2025179092A (ja) 2025-12-09
CN112955449B (zh) 2025-04-29
EA202190598A1 (ru) 2021-08-02
IL281258A (en) 2021-04-29
EP3849980A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JOP20210193A1 (ar) مثبطات pcsk9 وطرق استخدامها
PL3788044T3 (pl) Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
CL2020000408A1 (es) Formas sólidas cristalinas de un inhibidor de bet. (solicitud divisional 201803702).
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
EA201992584A1 (ru) Новые ингибиторы map4k1
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201790595A1 (ru) Пиримидиноны в качестве ингибиторов фактора xia
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
EA201691421A1 (ru) Гетероарилы и их применение
ECSP066833A (es) Compuestos heterocíclicos anticitocina
EP3810091B1 (en) COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
TN2017000213A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
EP3566055C0 (en) SCD INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
MX2018013797A (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso.
CU20160032A7 (es) Derivados de fenilalanina sustituidos
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EP3836922C0 (en) USE OF RILUZOLE ORODISPERSIBLE TABLETS FOR THE TREATMENT OF DISEASES
MX381425B (es) Compuestos heterociclicos biciclicos sustituidos.
EP4210720C0 (en) PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF ACNE
EP4058041C0 (en) COMPOSITIONS FOR THE TREATMENT OF EPITHELIAL INJURIES